Background/Aims: Neurotoxic A1 astrocytes are induced by inflammation after spinal cord injury (SCI), and the inflammation-related Nuclear Factor Kappa B (NFκB) pathway
Introduction
Traumatic spinal cord injury (SCI) is a severe type of central nervous system (CNS) damage that frequently leads to deleterious functional loss below the level of the injury. The pathophysiology of SCI is complex with immediate primary mechanical injury followed by a cascade of secondary processes including neuroinflammation, ischemia, and excitotoxity that exacerbate SCI damage [1] .
Astrocytes play a crucial role in SCI secondary injury referred to as reactive astrogliosis, which can both hinder and support CNS recovery [2] [3] [4] [5] . Liddelow et al. found that two types of reactive astrocytes, termed A1 and A2 astrocytes, are induced by neuroinflammation and ischemia, respectively [6] . A2 astrocytes exert protective effects by upregulating the expression of certain neurotrophic factors, whereas A1 astrocytes, which form rapidly after CNS injury, exert neurotoxic effects on the myelin sheath, synapses, and neurons. A recent study reported that neuroinflammatory A1 reactive astrocytes are induced by NFκB signaling [6] . Additionally, the marker of A1 astrocytes, complement component 3 (C3), is upregulated in an NFκB-dependent manner [7] . Moreover, blocking NFκB activity in astrocytes promotes oligodendrogenesis and axonal sparing through alteration of the inflammatory environment following SCI [8] .
Numerous studies have demonstrated MSCs as ideal candidates for cell-based treatment of SCI. MSCs promote tissue repair mainly by inhibiting inflammation and activating endogenous repair mechanisms [9, 10] . Previous studies demonstrated that MSCs reduce inflammatory cytokine (TNFα, IL-1, IL-6) levels [11] and inhibit NFκB activation under inflammatory conditions [12] . Additionally, MSCs are capable of directing stimulated macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype [13, 14] . Recent studies suggest that the therapeutic effects of MSCs might be mediated by exosomes [15] [16] [17] . Exosomes are small particles (40-100 nm in diameter) derived from multi-vesicular bodies and are secreted into extracellular fluid by most living cells. Exosomes carry complex cargo including proteins, lipids and nucleic acids, and transfer them to recipient cells to exert function. MSC-derived exosomes (MSC-exo) are reportedly capable of mimicking most biological functions of MSCs including anti-inflammatory and anti-apoptotic effects and can increase levels of anti-inflammatory cytokines, decrease levels of proinflammatory cytokines [18, 19] , and inhibit activation of astrocytes [17] and macrophages [20] . Similar to MSCs, MSC-exo infusion can inhibit NFκB activation [21, 22] . Moreover the therapeutic effects of cell-free exosomes are comparable with those of intact MSCs after brain injury [16, 17, 23] . A previous study of applications of MSC-exo to an SCI model suggesting that systemic administration reduced levels of proinflammatory cytokines and improved function recovery [24] ; however, the precise mechanisms associated with the beneficial effects on SCI remain unknown. Based on the reported anti-inflammatory effects, we hypothesized that both MSC and MSC-exo might play an inhibitory role on inflammationinduced A1 astrocytes.
In this study, we investigated the potential effect of MSCs and MSC-exo on A1 astrocytes after SCI. MSCs and MSC-exo derived from an equal number of MSCs were intravenously administered to SCI rats in order to evaluate their effect on A1 astrocytes in the ventral horn of the spinal cord, as well as the morphological reconstruction of the injured spinal cord and functional recovery. The astrocytes used in the experiments were purified from injured spinal-cord tissue and cultured in vitro to investigate the potential mechanism.
peroxidase-conjugated secondary antibody and bands were developed using enhanced chemiluminescence.
Analysis of size distribution was performed using tunable resistive pulse sensing (TRPS) on a qNano system (Izon, Christchurch, New Zealand). Briefly, samples or calibration particles were placed in the NP100A nanopore and measured with a voltage of 0.74 V.
MSC-exo lableling
MSC-exo were labeled with PKH26 dye (Sigma-Aldrich). Briefly, 2 µL of PKH26 was added to 1 mL of Diluent C containing 25 µg of exosomes, followed by incubation at 25°C for 20 min and the subsequent addition of 1 mL of 5% BSA to stop the staining reaction. Eight microliters of PBS was added to the mixture, followed by an ultra-centrifugation (4°C, 110, 000 g for 70 min). The pelleted exosomes were resuspended in 10 mL of PBS and ultra-centrifuged again (4°C, 110, 000 g for 70 min). The supernatant was removed and the exosomes were resuspended in PBS.
SCI models
For all rats, anesthesia was induced using 4% isoflurane in oxygen (1 L/min) and maintained with 2% isoflurane in oxygen (1 L/min). Laminectomy of a single vertebra at the level of T10 was performed to expose the spinal cord. Following this, a contusive injury (200 kilodyne) was applied to the exposed dura mater, using a spinal cord impactor (IH Impactor; Precision Systems and Instrumentation, Lexington, KY). The SCI models met the following inclusion criteria: spinal cord hemorrhage and edema around the wound, flicking of bilateral hind limbs, swaying reflex of the tail. The Sham group underwent only a laminectomy.
MSC or MSC-exo Injection
Rats were randomly divided into four groups: Sham, SCI rats receiving PBS (SCI+PBS), SCI rats receiving passage 4 MSCs (SCI+MSC), and SCI rats receiving MSC-exo (SCI+MSC-exo). For the SCI+MSC group, 200 µL PBS containing 1x10 Tissue preparation for immunofluorescence At 3 dpi, rats (n = 6) were anesthetized and perfused transcardially with 0.9% saline, followed by 4% paraformaldehyde in phosphate buffer (4℃; pH 7.4). A 1-cm long spinal cord segment, centered on the injury site was dissected, placed in the same fixative within 4 h to 6 h, and cryoprotected in sucrose solution (a graduated series of 10%, 20%, and 30%) at 4°C. These segments were cryosectioned into 20-µm-thick
sections.
Lesion size analysis At 28 dpi, the spinal cord specimens from each group were harvested (n = 6) and the 4% paraformaldehyde-fixed specimens were embedded into paraffin for production of 5-µm-thick transverse sections. Every 40 th section of the lesion-site sample was subjected to hematoxylin-eosin (HE) and Nissl staining. The middle three HE-stained sections (centered in the epicenter of the lesion site, with an interval of 200 µm) of each sample were used for lesion area analysis performed using ImageJ. Lesion percentage was calculated as the lesion area divided by the whole transverse area of the spinal cord.
TEM
Ultrathin sections of the injury site were observed by a transmission electron microscope (HITACHI) at 28 dpi (n = 4). The sections were collected on copper grids and counterstained with 2% uranyl acetate for 20 min and 0.04% lead citrate for 10 min.
ELISA
Spinal cord tissues were collected and homogenized as described for western blot. Concentrations of proinflammatory cytokines, including TNF-α, IL-1α and IL-1β, were measured using ELISA kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer's protocol. Assays were performed in duplicates, and data are expressed as pg/mg protein.
TUNEL assay
At 3 dpi, cell apoptosis on injury site was assessed using an in situ cell death detection kit (Roche, Mannheim, Germany) according to manufacturer's instructions. Tissue sections were dewaxed, rehydrated, and washed with PBS, followed by pre-treatment of the sections with proteinase-K for 30 min and incubation with TUNEL reaction mixture for 1 h at 37°C. The converter POD was then added to the sections. After incubation for 30 min at 37°C, the sections were washed with PBS and incubated with diaminobenzidine for 10 min. Images were captured using a microscope at 400× magnification.
Astrocytes isolation
Astrocytes were isolated according to previous methods [25, 26] . At 3d post SCI, rats from the Sham and SCI groups (n = 6) were sacrificed, and the T9-T11 segment of the ventral spinal cord was dissected from Sham rats while a 2-cm long ventral segment that included the rostral and caudal areas to the injury epicenter was removed from SCI rats. The spinal cord tissues were minced by mechanical shearing and then digested in PBS containing 0.125% trypsin and 0.01% papain for 30 min at 37°C. After centrifugation at 1000 g for 5 min, cells were re-suspended in DMEM/F12 supplemented with 10% exosome-depleted FBS and penicillin-streptomycin (Gibco). Cells were cultured for 7 days at 37°C under 5% CO2, with changes to the medium 3-days post plating. After 7 days, microglia and oligodendrocytes were removed by shaking the culture flasks at 210 rpm for 6 h at 37 °C. The astroglia phenotype of Glial Fibrillary Acidic Protein (GFAP) was characterized by immunofluorescence.
Astrocyte coculture with MSCs or MSC-exo
Seven groups were used for in vitro experiment: astrocytes isolated from Sham rats (Sh-AST); astrocytes isolated from SCI rats (SCI-AST); astrocytes isolated from SCI rats and supplemented with Pyrrolidine Dithiocarbamate (PDTC), an inhibitor of NFκB which inhibits the nuclear translocation of NFκB p65 [27] by suppressing the degradation of IKB (SCI-AST+PDTC); astrocytes isolated from SCI rats and co-cultured with MSC (SCI-AST+MSC); astrocytes isolated from SCI rats, co-cultured with MSC and supplemented with TNF-α, an activator of NFκB (SCI-AST+MSC+TNFα); astrocytes isolated from SCI rats and co-cultured with MSC-exo (SCI-AST+MSC-exo); astrocytes isolated from SCI rats, co-cultured with MSC-exo, and supplemented with TNF-α (SCI-AST+MSC-exo+TNFα). Cocultures were established using a 6-well Transwell cell culture system with a 0.4-μm membrane that cells cannot get through. For the SCI-AST+PDTC group, 5×10 4 astrocytes were seeded on the upper chamber and supplemented with 10 mM PDTC [27] [28] [29] . For the SCI-AST+MSC and SCI-AST+MSC+TNFα groups, 5×10 4 astrocytes were seeded on the upper chamber in the absence and presence of TNF-α (50 ng/mL; R&D Systems), respectively [30] [31] [32] [33] [34] , with 5×10 4 MSCs seeded on the lower chamber. Cells were cultured in DMEM supplemented with 10% exosome-depleted FBS and co-cultured for 48h. For the SCI-AST+MSC-exo and SCI-AST+MSC-exo+TNFα groups, MSCs were first seeded in 6-well plates (5×10 4 / well) and cultured for 48h, followed by collection of the supernatants to isolate exosomes, which were placed in the lower chamber and co-cultured with 5×10 4 astrocytes for 48h. Astrocytes co-cultured with MSCs or MSC-exo were then harvested for immunofluorescence and western blot analyses.
Immunofluorescence
The 20-µm cryo-sections (200-µm rostral to the injury epicenter; n = 6) and the astrocytes cultured in Transwells (n = 6) were washed in PBS and incubated with 5% BSA to block nonspecific antibody binding. The sections were first incubated with the following primary antibodies overnight at 4°C: rabbit anti-C3 ( 
Western blot
The T10 segment of the spinal cord was rapidly collected at 3 dpi (n = 6), and the ventral section was dissected for western blot analysis. Astrocytes were harvested at 48 h after co-culture (n = 6), and proteins from cytoplasm and nuclear fraction were separately extracted using a nuclear protein extraction kit (R0050; Solarbio). Forty micrograms of proteins was separated and transferred onto polyvinylidene fluoride membranes, which were blocked in blocking buffer for 2 h and then incubated with primary antibodies against p65 (1:1000; #8242; Cell Signaling Technology, Danvers, MA, USA), phosphorylated-p65 (1:1000; #3033; Cell Signaling Technology), p-IKBα(1:1000; #2859; Cell Signaling Technology), IKBα (1:1000; #4812; Cell Signaling Technology), GFAP (1:500; SAB4300647; Sigma), C3 (1:100; ab11887; Abcam), β-actin (1:1000; 20536-1-AP; Proteintech), and Histone H3 (1:1000; #9715; Cell Signaling Technology) at 4°C overnight. After washing, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody, for 2 h at 25℃. Bands were developed using enhanced chemiluminescence and band intensity was quantified using ImageJ.
Statistical analysis
Statistical analyses were performed using Graph Pad Prism 5.0 (San Diego, CA, USA). All data are presented as mean ± standard error of the mean (SEM). The data analysis of BBB scores and inclined plane test was conducted using two-way analysis of variance with repeated measures. Other data were analyzed using one-way analysis of variance and a Bonferroni post-test. P<0.05 was considered statistically significant. 
Results

Identification and labeling of MSCs and MSC-exo
MSCs were obtained from the bone marrow of rats and cultured in dishes (Fig. 1A ). Passage 4 MSC adhered to the bottom of the culture dishes and grew with a fibroblastlike morphology (Fig. 1B) . The expression of mesenchymal markers CD90 (96.4%), CD29 (99.9%), and CD45 (0.11%) was measured by flow cytometry (Fig. 1C) , and MSCs stained red with PKH26 were observed by fluorescence microscopy (Fig. 1D) . The CCK8 assay revealed no significant differences in cell proliferation between MSCs and PKH26-labeled MSCs within 72 h (P>0.05, Fig. 1E ). 
Cellular Physiology and Biochemistry
Exosomes were isolated from passage-4 MSC-culture supernatant by ultracentrifugation ( Fig. 2A) , and TEM observation of MSC-exo samples showed the presence of numerous saucer-shaped vesicles (Fig. 2B) . MSC-exo stained red with PKH26 dye were observed by fluorescence microscopy (Fig. 2C) , with subsequent TRPS analysis showed a diameter distribution profile ranging from 30 nm to 150 nm (Fig. 2D) . We verified high levels of expression of the exosome markers, CD63, CD9 and CD81 in the MSC-exo samples (Fig. 2E ).
MSCs and MSC-exo reduce the proportion of A1 astrocytes in vitro
To assess the effects of MSCs and MSC-exo on A1-astrocytes in vitro, we isolated astrocytes from spinal cord tissue of the sham and SCI groups (Fig. 3A) . Astrocytes derived from SCI rats were co-cultured respectively with MSCs and MSC-exo in a Transwell system (Fig. 3A) . Astrocytes were observed at a magnification of ×100 (Fig. 3B) . At 6 and 12 h after co-culture with MSC-exo, astrocytes were harvested to determine the extent of MSC-exo internalization. We observed PKH26-labeled MSC-exo present in the cytoplasm of astrocytes, especially at 12 h after co-culture (Fig. 3C) . At 48 h after co-culture, immunofluorescence assays were performed (Fig. 3D) , and the proportion of A1 astrocytes was evaluated in each group by calculating C3 
MSCs and MSC-exo reduce the proportion of A1 astrocytes in ventral horn of spinal cord after SCI
To investigate the effect of intravenously-administered MSCs or MSC-exo on A1 astrocytes of SCI rats, the rats were randomly divided into four groups (Fig. 4A) , and we assessed whether intravenously-injected MSCs or MSC-exo arrive at the lesion site. The injured spinal cord was removed at 1 dpi and prepared for observation by fluorescence microscopy. PKH26-labeled MSC-exo were observed at the injury site, whereas PKH26-labeled MSCs were not detected (Fig. 4B) . Analysis of the proportion of C3 + GFAP + astrocytes on the ventral horn of the spinal cord in different groups (Fig. 4C ) revealed increases in SCI+PBS group (0.330±0.078) as compared with the Sham group (P<0.001, Fig. 4D ). Furthermore, both MSCs and MSC-exo treatment decreased SCI-induced activation of A1 astrocytes (P<0.01 and P<0.05, respectively), with the proportion of A1 astrocytes at 0.090±0.025 in the SCI+MSC group and 0.111±0.041 in the SCI+MSC-exo group.
Additionally, C3 and GFAP expression in the ventral spinal cord was evaluated by western blot (Fig. 5A) showing levels in the SCI+PBS group higher than those in the Sham group (P<0.001 and P<0.001, respectively; Fig. 5B ). At 3-days post-administration of MSCs, we observed attenuated C3 and GFAP expression relative to that in SCI+PBS rats (P<0.01 and P<0.01, respectively). MSC-exo treatment also resulted in decreased levels of C3 and GFAP (P<0.01 and P<0.05, respectively). Importantly, no significant differences were found in levels of C3 and GFAP between the SCI+MSC and SCI+MSC-exo groups (P>0.05). 
MSCs and MSC-exo attenuate proinflammatory cytokine expression in ventral spinal cord
after SCI Previous studies showed that A1 astrocytes can be induced by proinflammatory factors, such as TNF and IL-1 [6, 35] . Therefore, we performed the ELISA assays at 3 dpi to assess levels of TNF-α, IL-1α, and IL-1β in the ventral spinal cord of different groups. TNF-α was 160.665±17.095 pg/mg in the SCI+PBS group, which was significantly higher than that in the Sham group (58.304±4.083 pg/mg; P<0.001; Fig. 5C ). TNF-α in the SCI+MSC and SCI+MSC-exo groups were lower than that in the SCI+PBS group (107.724±12.059 and 102.671±13.713 pg/mg, respectively), with no significant difference between MSC and MSC-exo treatment groups (P>0.05). IL-1α and IL-1β levels in the SCI+PBS group were 24.605±4.378 and .01, and P<0.001, respectively); however, MSC or MSC-exo treatment reduced these levels relative to that observed in the SCI+PBS group, with no significant difference in cytokine levels observed between MSC and MSC-exo treatment groups (P>0.05).
MSCs and MSC-exo attenuate lesion size and improved functional recovery in SCI rats
Ten rats from each group were sacrificed at 28 dpi following behavioral analyses, and histopathological evaluation was performed in the spinal cord of those rats (6 rats for HE and Nissl, 4 rats for TEM; Fig. 6A ). The lesion percentages in the SCI+PBS, SCI+MSC, and SCI+MSC-exo group were 34.933±2.182%, 12.471±1.853%, and 10.034±2.105%, respectively, with significant changes in the treatment groups relative to the percentage measured in the SCI+PBS group (P<0.001 and P<0.001, respectively). The ultrastructure of the lesion tissue from all groups was observed using TEM (Fig.  6A ). In the Sham group, the myelin sheath and axons displayed intact structures, whereas in the SCI+PBS group, we observed loose, onion-like demyelination and degenerated axons. However, in the SCI+MSC and SCI+MSC-exo groups, these morphological phenomena were alleviated. At 1 and 3 dpi, neither the BBB scores nor the inclined-plane angles among the SCI+PBS, SCI+MSC, and SCI+MSC-exo groups showed any significant difference (P>0.05; n = 10; Fig.  6C, D) . However, the SCI+MSC and SCI+MSC-exo groups showed significantly higher BBB scores than the SCI+PBS group from 7 dpi (7 dpi: P<0.001 and P<0.001;14 dpi: P<0.001 and P<0.001; 21 dpi: P<0.001 and P<0.001; 28 dpi: P<0.001 and P<0.001). At 28 dpi, the BBB scores in the MSC and MSC-exo treatment groups were 13.800±0.396 and 14.450±0.411, respectively, differences between which were not significant (P>0.05). The inclined-plane angles at 28 dpi in the MSC and MSC-exo treatment groups were 55.250±0.786° and 58.750±1.070°, respectively.
These results suggested that MSC and MSC-exo treatment attenuated lesion size and improved functional recovery after SCI. Additionally, the effects of MSCs and MSC-exo on functional recovery were equivalent.
MSCs and MSC-exo exert neuroprotective and anti-apoptotic effects on SCI rats
A1 astrocytes are toxic to synapses, myelin sheath, and neurons in the CNS. As a specific marker for presynaptic terminals, Syn is often used to detect the synapse density and distribution. MBP is the major protein of the myelin sheath in the CNS and maintains myelin sheath stability. NeuN is a neuron-specific nuclear protein that serves as an excellent marker for neurons in the central and peripheral nervous systems. To assess the loss of synapses, myelin sheath and neurons in injured spinal cord from different groups, Syn, MBP, and NeuN expression was detected, respectively, by immunofluorescence (Fig. 7A) . The percentages of Syn + area in the Sham, SCI+PBS, SCI+MSC, and SCI+MSC-exo groups were 30.213±1.529%, 4.250±1.814%, 13.565±2.088%, and 16.067±2.671%, respectively (Fig. 7C) To assess apoptosis, a TUNEL assay was performed in tissue from the ventral horn of spinal cords from all groups (n = 6). As shown in Fig. 7B , TUNEL-positive cells were rarely observed in the Sham group, whereas the percentage of TUNEL-positive cells was significantly higher in the SCI+PBS group (50.357±5.292%; Fig. 7D ) than in the Sham group (4.522±0.662%; P<0.001). Both the SCI+MSC and SCI+MSC-exo groups showed lower percentages of TUNEL-positive cells (25.638±4.771% and 21.085±5.211%, respectively) relative to the SCI+PBS group (P< 0.01 and P<0.001, respectively).
MSCs and MSC-exo inhibit SCI-induced nuclear translocation of the NFκB p65 subunit in astrocytes
Previous reports demonstrated that C3 is an astroglial target of NFκB, and that A1 astrocytes are induced by NFκB activation [6, 7] . Expression and distribution of the NFκB p65 subunit in the spinal cord was detected by immunofluorescence and western blot (Fig. 8A, C) . The expression levels of p-IKBα (NF-kappa-B inhibitor alpha) and nuclear p65 (p-p65) in the ventral spinal cord were significantly elevated in the SCI+PBS group as compared with those in the Sham group (P<0.001 and P<0.001, respectively; Fig. 8D ). Additionally, in the SCI+PBS group, the expression of cytoplasmic IKBα in ventral spinal cord decreased as 
MSCs and MSC-exo reduce A1 astrocytes via inhibiting the nuclear translocation of NFκB p65
To verify whether A1 astrocyte reductions following MSC and MSC-exo treatment were mediated by NFκB, we measured the percentage of p65 + nuclei in GFAP + cells, as well as the proportion of A1 astrocytes in the seven groups (Fig. 9A) . Immunofluorescence images showed the p65/GFAP/DAPI and C3/GFAP/DAPI-staining of different groups, respectively (Fig. 9B, C) .
The percentage of p65 + nuclei and the proportion of A1 astrocytes in the SCI-AST group were 16.750±2.071% and 0.139±0.033, respectively, which were higher than those observed in the Sh-AST group (P<0.001 and P<0.001, respectively; Fig. 9D, E) . Compared with the 
untreated SCI-AST, PDTC treatment reduced the percentage of p65 + nuclei (3.295±0.803%) and the proportion of A1 astrocytes (0.030±0.010). In the SCI-AST+MSC group, the percentage of p65 + nuclei and the proportion of A1 astrocytes were 3.760±0.884% and 0.019±0.011, respectively, and in the SCI-AST+MSC-exo group, these values were 4.072±0.869% and 0.023±0.012, respectively, with no significant difference observed in the values among the SCI-AST+PDTC, SCI-AST+MSC, and SCI-AST+MSC-exo groups. However, upon treatment of astrocytes with excess TNF-α, the reducing effects of MSCs and MSC-exo on p65 + nuclei and A1 astrocytes were attenuated.
Additionally, we evaluated the expression levels of A1 markers (C3 and GFAP) and NFκB-related proteins (p-IKBα, IKBα, p65 and p-p65) in different groups by western blot (Fig 10A) . The results revealed increased levels of C3, GFAP, p-IKBα, and nuclear p-p65, and decreased expression of IKBα in the SCI-AST group as compared with that in the Sh-AST group (p < 0.01, p < 0.01, p < 0.01, p < 0.001, and p < 0.001, respectively; Fig. 10B ). Treatment with PDTC, MSC, or MSC-exo reduced the levels of C3, GFAP, p-IKBα, and nuclear p-p65, and increased the expression of IKB-α in astrocytes (Fig. 10B) , with no significant difference observed in these protein levels between the MSC and MSC-exo treatment groups (p > 0.05). Moreover, the effects of MSC-exo treatment on C3, GFAP, p-IKBα, IKBα, and nuclear p-p65 levels and those of MSC treatment on the expression of C3, IKBα, and p-p65 were attenuated 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry by excess TNFα, whereas GFAP and p-IKBα levels showed no significant difference between the SCI-AST+MSC and SCI-AST+MSC+TNFα groups (p > 0.05). In summary, these results implied that MSCs and MSC-exo may reduce A1 astrocytes via inhibiting the nuclear translocation of p65.
Discussion
In this study, we provided the first evidence showing that MSCs and MSC-exo significantly reduced A1 astrocyte proportion by inhibiting NFκB activation, which resulted in their comparable beneficial effects on an SCI rat model. The intravenously applied MSCs and MSCexo contributed to an improved locomotor function, reductions in proinflammatory cytokine levels, and the neuroprotective effect on residual neurons, synapses, and myelin sheath.
Following primary mechanical injury, limiting the development of secondary injury is key to treating SCI. Reactive astrocytes play a significant role in secondary injury in SCI, with "reactive astrocyte'' first described during the 1970s after discovery of GFAP [36] , which is currently used as a routine identifier of astrocytes in the healthy CNS. Elevated GFAP level is considered a marker of astrocyte reactivity [37] . Numerous studies report that reactive astrocytes rather than a single type, are highly heterogeneous, and that neuroinflammation and ischemia can induce two different types of reactive astrocytes, "A1" and "A2," respectively. This terminology is similar to the nomenclature of microglia in the CNS, termed "M1" and "M2" [38, 39] . Additionally, previous studies demonstrated that A1 astrocytes might be activated via NF-κB signaling [6] . A1 astrocytes lose most of their original astrocyte function and exhibit new functions where they secrete toxins that induce apoptosis of neurons and are toxic to synapses and the myelin sheath. C3 is a marker for A1 astrocytes but not expressed in A2 astrocytes [6, 35, 37, 40] . In this study, C3/GFAP was used as a double-marker for labeling A1 reactive astrocytes in the spinal cord.
MSC have been shown to promote anatomical and functional recovery in SCI models [41, 42] . Early intravenous delivery of MSC attenuates injury by regulating inflammation in SCI [43] and traumatic brain injury (TBI) [44] [45] [46] . Additionally, MSC transplantation can reduce the levels of proinflammatory cytokines, such as TNF-α and IL-1 [11, 47] , and inhibit NFκB signaling [12, 48, 49] . Moreover, MSCs are capable of switching microglia from a proinflammatory M1 phenotype towards an anti-inflammatory M2 phenotype in vitro [13] and in SCI models [50] . Furthermore, MSCs inhibit reactive astrogliosis in inflammationinduced preterm brain injury [51] , attenuate GFAP overexpression in astrocytes in stroke [52] , and modulate astrocytic end-feet in lipopolysaccharide-treated rats [53] . However, little is known about the effect of MSCs on inflammatory A1 astrocytes after SCI.
Initially cell replacement potential was considered as the mechanism through which MSCs exert therapeutic function in injury repair [54] ; however, little evidence exists supporting transplanted-MSCs differentiation into functional cells in vivo [55] . Instead, paracrine capacity is a more important factor in the therapeutic effects provided by MSCs. The systemic administration of conditioned medium or the secretome from MSCs promotes recovery after SCI [56] and improves the outcomes of TBI in rats [57] . Recent studies showed that extracellular vesicles (EVs)/exosomes alone contributed to the therapeutic effects of MSCs in multiple animal models, such as those for ischemic stroke [16, 58, 59] , acute kidney injury [60] and traumatic brain injury [17] . Exosomes comprise one of the main subclasses of EVs and are considered the most promising therapeutic mediator of MSC function by altering the activity of target cells via horizontal transfer of mRNAs, microRNAs, and proteins [61] . Compared with factors in the absence of membrane packaging, exosomes are more stable and capable of targeting inflammatory sites due to their enhanced permeability and retention effects [62, 63] . MSC-exo have been confirmed to exert beneficial effects on functional recovery and suppress the activation of A1 neurotoxic reactive astrocytes after SCI [24, 64] ; However, it remains unclear whether these effects are comparable to those of live MSCs when applied systemically to SCI rats. In addition, the underlying mechanisms of Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the A1-inhibitory effects exerted by MSC-exo have not been investigated before. This is the first study to compare the efficacy of MSCs and cell-free exosomes derived from MSCs on SCI models. MSCs and exosomes secreted by an equal number of MSCs were applied to SCI rats via tail vein. Given that the permeability of the blood-spinal cord-barrier (BSCB) increased significantly at the lesion site at 1 and 3 days post-SCI, fell greatly by 1 week post-SCI, and remained stable at uninjured sites [65] , the ability of MSCs or exosomes to pass through the BSCB may be higher at injection time points within 1-week-post-SCI. Additionally, the inflammatory response develops within hours after SCI [66] ; therefore, in this study, the first time point of intravenous-injection was chosen at 30 min post SCI to ensure that MSCs or MSC-exo exerted their functions at the beginning of the inflammatory cascade in spinal cord. Then the second injection was performed at 1 dpi to strengthen the effects. Our findings suggested that both MSCs and MSC-exo displayed suppressive effects on A1 astrocytes, and showed an equal neuroprotective effect following SCI. Consistent with previous studies showing that MSC application decreased GFAP expression [67, 68] , we found the MSCs and MSC-exo not only downregulated the general reactivity of astrocytes (GFAP) but also reduced the A1 proportion in the whole astrocytes.
Notably, PKH26-labeled exosomes were present at lesion sites, whereas PKH26-labeled MSCs were not detected at lesion sites. This finding has been previously and consistently observed: intravenously administered MSCs were not detected at lesion sites of SCI, whereas they showed beneficial effects on functional recovery [42, 65] . However, in immunosuppressed rats, intravenously applied MSCs migrated to the lesion sites of SCI [69] or cerebral ischemia injury [70] , although no engrafted MSCs were detected at lesion sites 3 weeks post administration [71] . These results suggest that the differentiation ability and direct cell-tocell contact are not the primary mechanisms that mediate the therapeutic functions of MSCs in injury repair. Although in the SCI models we work with, the efficacy of purified exosomes is equivalent to that of live MSCs, it is possible that MSCs exert other important functions undetected in this study. There are other components such as microvesicles (>500 nm in diameter) and tunneling tubes that might be involved in MSC functions [72] [73] [74] [75] . However, in the present study, our results indicated that exosomes secreted by MSCs played a major role in the therapeutic function of intravenously administered MSCs in the SCI model.
NFκB signaling is widely activated after SCI [76] by multiple pro-inflammatory agents, such as cytokines (TNF-α and IL-1), stress, free radicals, and reactive oxygen species [77, 78] . Moreover, secondary inflammation in SCI is regulated by NFκB pathway [79] , and inhibition of astroglial NFκB improves functional recovery after SCI [76] . In unstimulated cells, NFκB exists in the cytoplasm in the form of a complex with IKB, an NFκB inhibitor. When stimulated by proinflammatory cytokines, such as TNF-α [32] and IL-1, NFκB is activated. The activation of NFκB involves the phosphorylation and degradation of IKB, followed by the nuclear translocation of the NFκB p65 subunit. The nuclear-translocated NFκB units exert the function as a transcription factor that positively regulate the transcription of target genes by binding to their promoter regions [80, 81] . As a target gene of NFκB, the C3 promoter contains two κB binding sites [82, 83] . Additionally, C3 is a direct NFκB target in astroglia [84] , and C3 + A1 astrocytes are induced through NFκB signaling. Therefore, we hypothesized that reductions in A1-astrocyte proportion following MSC or MSC-exo administration might be mediated by NFκB. Treatment with MSCs or MSC-exo attenuated the nuclear translocation of p65 accompanied by reductions in the proportion of the A1 subtype in cultured astrocytes. However, these effects were attenuated by excess TNF-α (an activator of NFκB). Although the direct interaction of p65 with C3 was not evaluated in the present study, we verified that MSC and MSC-exo reduced the A1 astrocyte proportion, at least partially through inhibition of NFκB p65 translocation/activation. Furthermore, we used a co-culture system that precluded direct MSC contact with astrocytes to ensure that the effect of the MSCs was mediated by their paracrine function. The exosomes secreted by an equal amount of MSCs exerted comparable effects on NFκB activation and reductions in the A1 subtype to live MSCs, indicating that among the paracrine components of MSCs, exosomes might play a central role in inhibiting NFκB p65 activation and reducing A1 astrocytes.
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
Previous researches have showed that MSC-exo may have multiple cell targets in the CNS. Nakano et al. reported that intraventricularly infused PKH26 labeled MSC-exo localized mainly to astrocytes in diabetic mouse brains [85] . Likewise, in a paper by Xiong et al., intravenously injected CD63 GFP-tagged MSC-exo were found taken up by neurons and astrocytes in traumatic brain injury rat brains [86] . However, a recent study reported that intravenously delivered DiR-labeled MSC-exo were detected predominantly within M2 macrophages, but only a small amount of them localized within astrocytic process endings in contused spinal cord [87] . It shall be noted that in this study, DiR-labeled MSC-exo were infused at one week post-contusion, whereas in our study, PKH26-labeled MSC-exo were infused at 30-min and 1-day post-injury. Considering the dynamic pathophysiological process after SCI, the different infusion time points may lead to diverse cellular localization for infused MSC-exo.
Here we focused on the effects of MSCs and MSC-exo on A1 astrocytes which are induced by SCI. However, we did not investigate other types of cells which may be involved in the activation of A1 astrocytes, such as microglia/macrophages and neutrophil. Activated microglia/macrophages and immune cells at the lesion site after SCI can produce a series of proinflammatory cytokines, including TNF-α, IL-1 and IL-6 [88, 89] that may lead to the activation of astroglial NFκB. Given that both MSCs and MSC-exo have been confirmed to inhibit proinflammatory microglia in SCI [50] , it is possible that MSCs and MSC-exo exert effects on A1 astrocytes not only in a direct way but also mediated by a variety of inflammatory cells.
Conclusion
In conclusion, the present study may provide a useful roadmap for future work on the mechanistic research about cell-free therapy for CNS injury.
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